Payment overview · 2025
General Payments
$417.64
13 reported records · 11 companies
Healthcare provider profile · identity verified
Corbin Ballam, DO
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1205282894
Verified facts
What the public records show
CMS Open Payments records show Corbin Ballam, DO received $417.64 in general payments during 2025 across 13 reported records.
Penumbra, Inc. accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $170.85 | 40.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.68 | 10.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.91 | 7.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.61 | 6.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.10 | 5.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.75 | 5.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.02 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.46 | 4.9% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.25 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.20 | 4.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.81 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.64 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $170.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1482 | 434 |
| Losartan Potassium | Losartan Potassium | 985 | 303 |
| Levothyroxine Sodium | Levothyroxine Sodium | 880 | 263 |
| Lisinopril | Lisinopril | 847 | 261 |
| Tizanidine Hcl | Tizanidine Hcl | 813 | 283 |
| Amlodipine Besylate | Amlodipine Besylate | 802 | 243 |
| Gabapentin | Gabapentin | 507 | 142 |
| Montelukast Sodium | Montelukast Sodium | 489 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 488 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 441 | 141 |
| Metformin Hcl | Metformin Hcl | 420 | 137 |
| Bupropion Xl | Bupropion Hcl | 406 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 384 | 122 |
| Hydrochlorothiazide | Hydrochlorothiazide | 363 | 116 |
| Trazodone Hcl | Trazodone Hcl | 362 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 113 |
| Omeprazole | Omeprazole | 300 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 109 |
| Pravastatin Sodium | Pravastatin Sodium | 255 | 84 |
| Simvastatin | Simvastatin | 255 | 84 |
| Ezetimibe | Ezetimibe | 244 | 73 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 213 | 64 |
| Sertraline Hcl | Sertraline Hcl | 213 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 203 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 82 |
| Potassium Chloride | Potassium Chloride | 197 | 57 |
| Furosemide | Furosemide | 183 | 52 |
| Allopurinol | Allopurinol | 179 | 61 |
| Carvedilol | Carvedilol | 179 | 52 |
| Alprazolam | Alprazolam | 177 | 29 |
| Celecoxib | Celecoxib | 169 | 50 |
| Metformin Hcl Er | Metformin Hcl | 166 | 60 |
| Ozempic | Semaglutide | 151 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 144 | 40 |
| Eliquis | Apixaban | 143 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 42 |
| Jardiance | Empagliflozin | 123 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 120 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 115 | 16 |
| Xarelto | Rivaroxaban | 114 | 31 |
| Finasteride | Finasteride | 110 | 32 |
| Clonazepam | Clonazepam | 104 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 104 | 30 |
| Atenolol | Atenolol | 101 | 33 |
| Farxiga | Dapagliflozin Propanediol | 100 | 21 |
| Dutasteride | Dutasteride | 97 | 31 |
| Pregabalin | Pregabalin | 94 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 25 |
| Lorazepam | Lorazepam | 90 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 85 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 23 |
| Synthroid | Levothyroxine Sodium | 79 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 26 |
| Alendronate Sodium | Alendronate Sodium | 72 | 22 |
| Ondansetron Odt | Ondansetron | 72 | 21 |
| Donepezil Hcl | Donepezil Hcl | 70 | 22 |
| Tramadol Hcl | Tramadol Hcl | 69 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 69 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 64 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 17 |
| Buspirone Hcl | Buspirone Hcl | 62 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 62 | 25 |
| Propranolol Hcl | Propranolol Hcl | 62 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 21 |
| Spironolactone | Spironolactone | 59 | 18 |
| Valacyclovir | Valacyclovir Hcl | 59 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 18 |
| Terazosin Hcl | Terazosin Hcl | 54 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 29 |
| Meloxicam | Meloxicam | 51 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 14 |
| Irbesartan | Irbesartan | 50 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 49 | 15 |
| Glipizide | Glipizide | 48 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 12 |
| Mounjaro | Tirzepatide | 47 | 11 |
| Lovastatin | Lovastatin | 46 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 12 |
| Valsartan | Valsartan | 46 | 15 |
| Mirtazapine | Mirtazapine | 45 | 15 |
| Benazepril Hcl | Benazepril Hcl | 44 | 11 |
| Ketoconazole | Ketoconazole | 44 | 20 |
| Prednisone | Prednisone | 44 | 28 |
| Chlorthalidone | Chlorthalidone | 43 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 15 |
| Estradiol | Estradiol | 39 | 19 |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Creon | Lipase/Protease/Amylase | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 25 |
| Glipizide Er | Glipizide | 36 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 35 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | 13 |
| Acyclovir | Acyclovir | 34 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Baclofen | Baclofen | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 29 |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | 13 |
| Methocarbamol | Methocarbamol | 30 | 13 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 16 |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Azithromycin | Azithromycin | 27 | 24 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Famotidine | Famotidine | 25 | 11 |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Prolia | Denosumab | 24 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Diazepam | Diazepam | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 11 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $417.64 · 13 records | Penumbra, Inc. | BREZTRI, CAPVAXIVE, CREON, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, Indigo System, Kerendia, LOREEV XR, Ozempic, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error